Progression-free survival in patients with chronic myeloid leukemia with a major molecular response may be predicted 2.5 years after diagnosis.


Cognitive dysfunction among older patients with hematologic cancer may be predictive of mortality.
A recent study investigated the most common causes of treatment failure for patients with complex karyotype acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Treatment-free remission seems to be feasible for patients with chronic myeloid leukemia who achieve a sustained deep molecular response after discontinuing second-line therapy.
Initial treatment of adult patients with acute myeloid leukemia at National Cancer Institute-designated cancer centers has been linked to a 53% reduction in the odds of early mortality.
Subscribe to Blood Cancer